USO 25236

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Disease Types: Lymphoma & Hematologic

Eligibility Requirements:

• Histologically confirmed DLBCL by prior biopsy per WHO
classification, including but not limited to DLBCL-NOS, leg-type
DLBCL, EBV+ DLBCL, and T-cell/histiocyte-rich DLBCL
• Subject must have PET-positive disease at screening, defined as 4 to
5 on the Lugano 5-point scale
• Received no prior treatment for DLBCL
• ECOG ≤2; IPI score 2-5
• Subjects with ECOG status of 2 or IPI score of 2 will be capped
at 20% per arm
• Subjects with transformed indolent lymphoma to DLBCL,
PMBCL/grey zone lymphoma, or Ann Arbor Stage I DLBCL are
excluded
For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Suffolk (Harbour View)
• Virginia Beach (Princess Anne)
• Williamsburg